Skip to Content
Søg Menu

Adjuvant pembrolizumab for resected high-risk stage melanoma decreased the risk of death

In this MEDtalk Jason Luke, associate professor, presents the results from KEYNOTE-716 study, where patients with high-risk stage melanoma were treated with pembrolizumab (pembro) versus placebo in pts with resected AJCC-8 stage IIB or IIC melanoma

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Marco Donia

ESMO 2023 Highlights: Developments in Melanoma

/ Marco Donia
ESMO23Melanom Play the Video 03:46

Significant PFS Benefit for the Nivolumab + Relatlimab Combination for Patients with Unresectable or Metastatic Melanoma

/ BestPractice Nordic
ASCO23Melanom

Adjuvant Pembrolizumab Continue to Demonstrate Significant Improvements for Patients with Stage IIB/IIC Melanoma

/ BestPractice Nordic
ASCO23Melanom

Borderline Ovarian Tumors Increase Risk of Some Non-Ovarian Cancers

/ Susanne Krüger Kjær / Charlotte Gerd Hannibal
MelanomGynækologisk cancerLungecancerPancreascancerLeukæmi

LAG3-hæmmere ændrer immunterapiens behandlingslandskab

/ Marco Donia / Eva Ellebæk
MelanomImmunterapi

Occupation and cutaneous melanoma in the Nordic countries: A 45-year follow-up of 14,9 million people

/ Jose Hernán Alfonso
ArbejdsmiljøHudcancerMelanomCancer
Paolo Antonio Ascierto

Current landscape in the immuno-oncology treatment of non-melanoma skin cancers

/ Paolo Antonio Ascierto
ESMO22MelanomCancer Play the Video 6:28
Michael B. Atkins

Treatment sequence should begin with Nivo+Ipi in patients with MM

/ Michael B. Atkins.
Melanom Play the Video 7:28
Prof. Gerard Zalcman

Firstline nivolumab plus ipilimumab shows durable OS after 4 years in patients with pleural mesothelioma

/ Gerard Zalcman
ESMO22Melanom Play the Video 3:59
Back to top